文献速递哮喘慢阻肺呼吸道感染

呼吸疾病中的微生物组-肠-肺轴:从生物学机制到临床转化

The Microbiome-Gut-Lung axis in Respiratory Diseases: From Biological Mechanisms to Clinical Translation.
PubMed 文献 · Respirology · 2026-10-12

本综述阐述微生物组-肠-肺轴在呼吸疾病发病中的作用,包括代谢物驱动的免疫调节、模式识别受体信号及免疫生态重塑等核心机制。文章汇总该轴与哮喘、慢阻肺、囊性纤维化、支气管扩张、肺炎及脓毒症相关ARDS的表型特异性证据,并讨论肠-肺特征作为生物标志物和可治疗特征的转化前景及微生物组靶向干预。

要点

  • 肠-肺轴通过微生物代谢物和结构成分双向调节肺免疫与肠道菌群。
  • 该轴失调可能影响呼吸疾病易感性、进展和临床表现。
  • 肠-肺特征有潜力作为生物标志物和可治疗特征。

核心结论

  • 微生物组-肠-肺轴参与呼吸疾病发病,失调可能影响疾病易感性、进展和临床表现。

研究设计与样本

  • 综述,检索并汇总微生物组-肠-肺轴与呼吸疾病相关的机制和临床证据。

主要发现

  • 肠源性微生物代谢物和结构成分可调节肺免疫,呼吸道感染和暴露可反向影响肠道菌群。
  • 核心机制包括代谢物驱动的免疫调节、模式识别受体信号和双向免疫生态重塑。
  • 表型特异性证据涉及哮喘、慢阻肺、囊性纤维化、支气管扩张、肺炎和脓毒症相关ARDS。

临床怎么用

  • 关注肠-肺特征作为生物标志物和可治疗特征的转化潜力。
  • 现有具微生物组效应的疗法和新兴微生物组靶向干预可能用于临床管理。

局限性

  • 综述指出该领域存在关键挑战并提出未来研究优先方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory diseases exhibit substantial heterogeneity in clinical phenotypes and underlying pathobiology that cannot be fully captured by conventional lung-centred frameworks. Accumulating evidence implicates a role for the microbiome-gut-lung axis in respiratory disease pathogenesis. Within this bidirectional axis, gut-derived microbial metabolites and structural components can modulate pulmonary immunity, whereas respiratory infection and exposures can reciprocally influence the gut microbiota. Dysregulation of the microbiome-gut-lung axis may influence respiratory disease susceptibility, progression, and clinical presentation. In this Review, we outline core mechanisms of gut-lung crosstalk, including metabolite-driven immunomodulation, pattern recognition receptor signalling and reciprocal immune-ecological remodelling. We synthesize phenotype-specific evidence linking the axis to major chronic inflammatory airway diseases (asthma, chronic obstructive pulmonary disease, cystic fibrosis and bronchiectasis) and acute respiratory disorders (pneumonia and sepsis-associated acute respiratory distress syndrome), emphasizing mechanistic and clinical evidence. We discuss the translational promise of gut-lung signatures as biomarkers and treatable traits and review current therapies with microbiome effects and emerging microbiome-targeted interventions. Finally, we address key challenges and propose future research priorities to advance clinical management leveraging the gut-lung axis.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Yang Y, Tang X, Chen R, et al. The Microbiome-Gut-Lung axis in Respiratory Diseases: From Biological Mechanisms to Clinical Translation. Respirology. 2026. PMID: 42864764. doi:10.1002/resp.70329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。